<u>AMENDMENT</u>

IN THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions and listings of the claims in the present application.

Claims 1-20. (Cancelled)

21. (New) A method of lowering plasma glucagon in a subject in need thereof, comprising:

identifying a subject in need of therapeutic lowering of plasma glucagon levels; and administering to said subject a composition comprising a therapeutically effective glucagon lowering amount of an exendin, an exendin analog or combinations thereof;

wherein said exendin and exendin analog each have an amino acid sequence that is more than 30 amino acid residues in length.

- 22. (New) The method of claim 21, wherein said subject is suffering from necrolytic migratory erythema.
 - 23. (New) The method of claim 21, wherein said subject has a glucagonoma.
- 24. (New) The method of claim 21, wherein the subject has a diabetes-related disorder.
 - 25. (New) The method of claim 24, wherein the subject has type 2 diabetes.
 - 26. (New) The method of any of claims 21-25, wherein said subject is a human.
- 27. (New) The method of claim 21, wherein said composition is provided in a dosage unit form without another anti-glucagon agent.
- 28. (New) The method of claim 21, wherein said composition comprises an exendin analog having an amino acid sequence selected from the sequences of SEQ ID NO: 47 and SEQ ID NO: 48.
- 29. (New) The method of claim 28, wherein said amino acid sequence has a sequence of SEQ ID NO: 47, wherein the Xaa in position 1 is His; the Xaa in position 2 is Gly; the Xaa in position 6 is Phe or naphthylalanine; the Xaa in position 14 is Leu, pentylglycine or Met; the Xaa in position 22 is Phe or naphthylalanine; the Xaa in position 23 is Ile or Val; the Xaa in position 25 is Phe, Tyr, or naphthylalanine; the Xaa in positions 31, 36, 37, and 38 are independently

selected from Pro, homoproline, thioproline, or N-alkylalanine; and the Xaa in position 39 is Ser or Tyr.

- 30. (New) The method of claim 28, wherein said amino acid sequence has a sequence of SEQ ID NO: 47, wherein the Xaa in position 14 is Leu or pentylglycine; and the Xaa in position 22 is Phe or naphthylalanine.
- 31. (New) The method of claim 28, wherein said amino acid sequence has a sequence of SEQ ID NO: 48, wherein the Xaa in positions 6 and 22 are independently selected from Phe or naphthylalanine; the Xaa in position 23 is Ile or Val; and the Xaa in positions 30, 36, 37, and 38 are independently selected from Pro, homoproline, thioproline, or N-alkylalanine.
 - 32. (New) The method of claim 21, wherein said composition comprises exendin-4.
- 33. (New) A method of lowering plasma glucagon in a subject, comprising: identifying a subject in need of therapeutic lowering of plasma glucagon levels; and administering to said subject a composition consisting essentially of a therapeutically glucagon lowering amount of an exendin, an exendin analog or combinations thereof;

wherein said exendin and exendin analog each have an amino acid sequence that is more than 30 amino acid residues in length.

- 34. (New) The method of claim 33, wherein said subject is suffering from necrolytic migratory erythema.
 - 35. (New) The method of claim 33, wherein said subject has a glucagonoma.
- 36. (New) The method of claim 33, wherein the subject has a diabetes-related disorder.
 - 37. (New) The method of claim 36, wherein the subject has type 2 diabetes.
 - 38. (New) The method of any of claims 33-37, wherein said subject is a human.
- 39. (New) The method of claim 33, wherein said composition consists essentially of an exendin analog having an amino acid sequence selected from the sequences of SEQ ID NO: 47 and SEQ ID NO: 48.
- 40. (New) The method of claim 39, wherein said amino acid sequence has a sequence of SEQ ID NO: 47, wherein the Xaa in position 1 is His; the Xaa in position 2 is Gly; the Xaa in position 6 is Phe or naphthylalanine; the Xaa in position 14 is Leu, pentylglycine or Met; the Xaa

in position 22 is Phe or naphthylalanine; the Xaa in position 23 is Ile or Val; the Xaa in position 25 is Phe, Tyr, or naphthylalanine; the Xaa in positions 31, 36, 37, and 38 are independently selected from Pro, homoproline, thioproline, or N-alkylalanine; and the Xaa in position 39 is Ser or Tyr.

- 41. (New) The method of claim 39, wherein said amino acid sequence has a sequence of SEQ ID NO: 47, wherein the Xaa in position 14 is Leu or pentylglycine; and the Xaa in position 22 is Phe or naphthylalanine.
- 42. (New) The method of claim 39, wherein said amino acid sequence has a sequence of SEQ ID NO: 48, wherein the Xaa in positions 6 and 22 are independently selected from Phe or naphthylalanine; the Xaa in position 23 is Ile or Val; and the Xaa in positions 30, 36, 37, and 38 are independently selected from Pro, homoproline, thioproline, or N-alkylalanine.
- 43. (New) The method of claim 33, wherein said composition consists essentially of exendin-4.